ArticleTropical diseases, travel medicine and vaccines2025
One-step ahead: evaluating the efficacy of single-visit rabies pre-exposure prophylaxis against conventional multi-visit protocol: a randomized non-inferiority clinical trial.
Article in Tropical diseases, travel medicine and vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevention of neuroinfectious-diseases: high impact of vaccination programs - but the potential is not maxed out yet.Neurological research and practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRabies, a universally fatal viral infection of the central nervous system, remains a significant public health challenge in endemic regions like India. Although pre-exposure prophylaxis (PrEP) is a critical preventive measure, logistical and financial barriers restrict its widespread implementation. The World Health Organization (WHO) has recommended single-visit PrEP schedules to overcome these challenges, necessitating their evaluation in endemic settings.
methodsA randomized, double-blind, non-inferiority clinical trial was conducted with 41 healthy, immunologically naïve participants divided into two groups. Group A received a multi-visit PrEP schedule (0.1 mL intradermally at two sites on days 0, 7). Group B underwent single-visit PrEP (0.1 mL at four sites on day 0). Antibody titers were measured using ELISA on days 0 and 28. Data were analyzed for seroconversion rates, immunogenicity, and influencing factors using statistical methods.
resultsIn Group A, 4 out of 5 (80%) participants showed sufficient seroconversion while 1 (20%) showed insufficient seroconversion, and in Group B, 26 out of 30 (86.67%) showed sufficient seroconversion and 4 (13.3%) showed insufficient seroconversion. Both groups showed significant increases in antibody seroconversion (OD)titres from baseline (p = 0.0038 for Group A, p < 0.0001 for Group B). Regression analysis indicated no significant influence of demographic factors on antibody levels. The single-visit schedule achieved comparable efficacy with fewer logistical barriers.
conclusionsSingle-visit PrEP schedules represent an effective and feasible alternative to conventional protocols, aligning with WHO recommendations. They offer a scalable solution to enhance rabies prevention in resource-constrained settings, although further research is needed to assess long-term immunity and broader applicability. CLINICAL TRIAL NUMBER: This study was registered and approved prospectively with CLINICAL TRIAL REGISTRY OF INDIA with the following registration number - CTRI APPROVAL NO – CTRI/2024/10/075093 registered on 10/10/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.